

Title (en)  
OPHTHALMIC COMPOSITIONS AND METHODS OF USE

Title (de)  
OPHTHALMISCHE ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG

Title (fr)  
COMPOSITIONS OPHTALMIQUES ET MÉTHODES D'UTILISATION

Publication  
**EP 3843721 A4 20221012 (EN)**

Application  
**EP 19856338 A 20190829**

Priority  
• US 201816116872 A 20180829  
• US 2019048721 W 20190829

Abstract (en)  
[origin: WO2020047197A1] The present invention relates to an ophthalmic composition comprising at least two active pharmaceutical ingredients. In particular, the active pharmaceutical ingredients are selected from the group consisting of: an alpha 2 adrenergic receptor agonist; a beta-adrenergic receptor agonist; an immunosuppressant; a lymphocyte associated antigen antagonist; an anti-inflammatory; a beta-blocker; a prostaglandin analog; a histamine receptor antagonist; a carbonic anhydrase inhibitor; and an antibiotic. In some embodiments, the composition of the invention is a nanoemulsion formulation. In one particular embodiment, the first active pharmaceutical ingredient is an alpha 2 adrenergic receptor agonist. The present invention also provides a method for treating various clinical conditions associated with an eye disorder or eye disease using the composition of the invention.

IPC 8 full level  
**A61K 31/417** (2006.01); **A61K 9/00** (2006.01); **A61K 9/08** (2006.01); **A61K 9/107** (2006.01); **A61K 31/137** (2006.01); **A61K 31/407** (2006.01); **A61K 31/436** (2006.01); **A61K 31/4725** (2006.01); **A61K 31/498** (2006.01); **A61K 31/56** (2006.01); **A61K 31/573** (2006.01); **A61K 38/13** (2006.01); **A61K 47/10** (2017.01); **A61K 47/12** (2006.01); **A61K 47/18** (2017.01); **A61K 47/26** (2006.01); **A61K 47/32** (2006.01); **A61K 47/44** (2017.01); **A61P 27/02** (2006.01)

CPC (source: EP)  
**A61K 9/0048** (2013.01); **A61K 9/1075** (2013.01); **A61K 31/137** (2013.01); **A61K 31/436** (2013.01); **A61K 31/4725** (2013.01); **A61K 31/498** (2013.01); **A61K 31/56** (2013.01); **A61K 38/13** (2013.01); **A61K 47/10** (2013.01); **A61K 47/12** (2013.01); **A61K 47/186** (2013.01); **A61K 47/26** (2013.01); **A61K 47/32** (2013.01); **A61K 47/44** (2013.01); **A61P 27/02** (2017.12)

Citation (search report)  
• [Y] EP 1827373 B1 20081203 - NOVAGALI PHARMA SA [FR]  
• [IY] US 9597328 B2 20170321 - JAIN SANDEEP [US], et al  
• [Y] US 2007225217 A1 20070927 - CHAPPELL TODD W [US], et al  
• [Y] US 2018055943 A1 20180301 - SALZMAN IRA JASON [US]  
• [Y] WO 2018139991 A1 20180802 - MACREGEN INC [US]  
• [Y] US 9034830 B2 20150519 - NANDURI PADMA [US], et al  
• [I] US 2018221278 A1 20180809 - ARUMUGHAM RASAPPA [US], et al  
• [I] US 2018153885 A1 20180607 - JAIN SANDEEP [US], et al  
• [Y] US 2017304316 A1 20171026 - SHAH MANDAR V [IN], et al  
• [Y] AU 2012351948 A1 20140710 - ALLERGAN INC [US]  
• See references of WO 2020047197A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2020047197 A1 20200305**; CA 3115664 A1 20200305; CN 111212642 A 20200529; EP 3843721 A1 20210707; EP 3843721 A4 20221012

DOCDB simple family (application)  
**US 2019048721 W 20190829**; CA 3115664 A 20190829; CN 201980001967 A 20190829; EP 19856338 A 20190829